🔴 Lantern Pharma is trading 5% down in pre-market as immediate catalyst remains unclear

Lantern Pharma is trading 5.04% lower at $1.32 versus its September 23 close of $1.39; the immediate catalyst is unclear amid weaker U.S. index futures and elevated Treasury yields.

• No fresh negative company-specific announcement was identified for September 24.
• The latest company news was a September 22 USPTO Notice of Allowance for an LP-284 treatment patent, potentially extending protection into 2042.
• Biotechnology shares were reportedly stronger pre-market.